Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.

Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ.

Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5855-9.

2.

An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro.

Tomita N, Horiuchi M, Tomita S, Gibbons GH, Kim JY, Baran D, Dzau VJ.

Am J Physiol. 1998 Aug;275(2 Pt 2):F278-84.

3.

Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates.

Kawauchi M, Suzuki J, Morishita R, Wada Y, Izawa A, Tomita N, Amano J, Kaneda Y, Ogihara T, Takamoto S, Isobe M.

Circ Res. 2000 Nov 24;87(11):1063-8.

4.

Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy.

Yoshimura S, Morishita R, Hayashi K, Yamamoto K, Nakagami H, Kaneda Y, Sakai N, Ogihara T.

Gene Ther. 2001 Nov;8(21):1635-42.

5.

Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model.

Kawamura I, Morishita R, Tomita N, Lacey E, Aketa M, Tsujimoto S, Manda T, Tomoi M, Kida I, Higaki J, Kaneda Y, Shimomura K, Ogihara T.

Gene Ther. 1999 Jan;6(1):91-7.

6.
7.
8.
9.

EGR-1 decoy ODNs inhibit vascular smooth muscle cell proliferation and neointimal hyperplasia of balloon-injured arteries in rat.

Han W, Liu GN.

Life Sci. 2010 Feb 13;86(7-8):234-43. doi: 10.1016/j.lfs.2009.12.005.

PMID:
20025889
11.

Functional interaction between DP-1 and p53.

Sørensen TS, Girling R, Lee CW, Gannon J, Bandara LR, La Thangue NB.

Mol Cell Biol. 1996 Oct;16(10):5888-95.

14.

Administration of a decoy against the activator protein-1 binding site suppresses neointimal thickening in rabbit balloon-injured arteries.

Kume M, Komori K, Matsumoto T, Onohara T, Takeuchi K, Yonemitsu Y, Sugimachi K.

Circulation. 2002 Mar 12;105(10):1226-32.

15.

Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia.

Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ.

Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8474-8.

16.

Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia.

Ahn JD, Morishita R, Kaneda Y, Kim HS, Chang YC, Lee KU, Park JY, Lee HW, Kim YH, Lee IK.

Gene Ther. 2002 Dec;9(24):1682-92.

17.

Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo.

Maeshima Y, Kashihara N, Yasuda T, Sugiyama H, Sekikawa T, Okamoto K, Kanao K, Watanabe Y, Kanwar YS, Makino H.

J Clin Invest. 1998 Jun 1;101(11):2589-97.

19.

Gene therapy with an E2F transcription factor decoy inhibits cell cycle progression in rat anti-Thy 1 glomerulonephritis.

Tomita N, Kim JY, Gibbons GH, Zhang L, Kaneda Y, Stahl RA, Ogborn M, Venderville B, Morishita R, Baran D, Dzau VJ.

Int J Mol Med. 2004 May;13(5):629-36.

PMID:
15067361
20.

Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.

Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, Orav EJ, Ehsan A, Dell'Acqua G, Dzau VJ.

Lancet. 1999 Oct 30;354(9189):1493-8.

PMID:
10551494

Supplemental Content

Support Center